E Point Perfect
Law \ Legal

Celltrion Obtains Canadian Approval To Sell Bevacizumab Biosimilar


This week, Celltrion obtained full label approval from Health Canada to sell Vegzelma (CT-P16), a bevacizumab biosimilar indicated for the treatment of metastatic colorectal cancer, non-small cell lung cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and glioblastoma.  Celltrion has secured sales licenses for Vegzelma in 35 countries, including Korea, Europe, U.K., and Japan.

The post Celltrion Obtains Canadian Approval To Sell Bevacizumab Biosimilar appeared first on Big Molecule Watch.


Source link

Related posts

Protecting Electronic Communications Networks and Services from Cyber-Attack and Data Breach: Enhanced Obligations and Board-level Accountability

APRA finalises guidance on contingent liquidity for Minimum Liquidity Holdings ADIs

Seventh Circuit Upholds Walmart Pregnancy Accommodation Win Over EEOC

FTC Proposes Outlawing Noncompetition Agreements

Why has Revive NOT recalled the Mango and Pineapple Smoothies that have sickened many?

Law Society of Ontario elects Jacqueline Horvat as new treasurer